Seoul National University Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2022

  1. Trastuzumab Deruxtecan for Breast Cancer. Reply

    The New England journal of medicine

2016

  1. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial

    The Lancet Oncology, Vol. 17, Núm. 3, pp. 357-366